



ABCC10 Plays a Significant Role in the Transport of Gefitinib and Contributes to Acquired Resistance to Gefitinib in NSCLC

Hongbo Zhao¹, Yutang Huang², Jingjing Shi², Yi Dai², Lanxiang Wu^{2*} and Honghao Zhou^{2,3}

¹ Shanghai Key Laboratory of Female Reproductive Endocrine Related Diseases, Obstetrics and Gynecology Hospital, Fudan University, Shanghai, China, ² Institute of Life Sciences, Chongqing Medical University, Chongqing, China,

³ Pharmacogenetics Research Institute, Institute of Clinical Pharmacology, Central South University, Changsha, China

OPEN ACCESS

Edited by:

Petr Pavek,
Charles University, Czechia

Reviewed by:

Zhihao Liu,
University of Illinois at Chicago,
United States
Cesare Indiveri,
Università della Calabria, Italy

*Correspondence:

Lanxiang Wu
lxwu2008@126.com

Specialty section:

This article was submitted to
Drug Metabolism and Transport,
a section of the journal
Frontiers in Pharmacology

Received: 04 September 2018

Accepted: 29 October 2018

Published: 20 November 2018

Citation:

Zhao H, Huang Y, Shi J, Dai Y, Wu L and Zhou H (2018) ABCC10 Plays a Significant Role in the Transport of Gefitinib and Contributes to Acquired Resistance to Gefitinib in NSCLC. *Front. Pharmacol.* 9:1312. doi: 10.3389/fphar.2018.01312

Gefitinib, an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (EGFR-TKI), is used clinically as first-line therapy in patients with advanced non-small cell lung cancer (NSCLC) with EGFR activating mutations, but the inevitable development of acquired resistance limits its efficacy. In up to 30–40% of NSCLC cases, the mechanism underlying acquired resistance remains unknown. ATP-binding cassette (ABC) transporters are a family of membrane proteins that can significantly influence the bioavailability of numerous drugs, and have confirmed to play an essential role in multidrug resistance (MDR) in cancer chemotherapy. However, their role in acquired resistance to gefitinib in NSCLC has not been well studied. Here, through RNA sequencing (RNA-Seq) technology we assessed the differentially expressed ABC transporters in gefitinib-sensitive (PC9 and H292) and gefitinib-resistant (PC9/GR and H292/GR) NSCLC cells, with ABCC10 identified as a transporter of interest. Both ABCC10 mRNA and protein were significantly increased in acquired gefitinib-resistant NSCLC cells, independent of EGFR mutation status. *In vitro* transport assay showed that ABCC10 could actively efflux gefitinib, with an efflux ratio (ER) of 7.8. Further results from *in vitro* cell line models and *in vivo* xenograft models showed that overexpression of ABCC10 led to a reduction in gefitinib sensitivity through decreasing the intracellular gefitinib accumulation. Our data suggest that ABCC10 has an important role in acquired resistance to gefitinib in NSCLC, which can serve as a novel predictive marker and a potential therapeutic target in gefitinib treatment.

Keywords: ABC transporter, ABCC10, gefitinib, acquired resistance, non-small cell lung cancer

INTRODUCTION

Lung cancer is by far the leading cause of cancer-related deaths in both men and women (Ridge et al., 2013). Non-small cell lung cancer (NSCLC) represents approximately 85% of all lung cancer case, with 5-year survival rates of only 16% (Tas et al., 2013). In 40–80% of NSCLCs, the epidermal growth factor receptor (EGFR) has been found to be overexpressed, which is believed

to contribute to the NSCLC cell proliferation, differentiation, and survival (Ennis et al., 1991; Salomon et al., 1995; Jutten and Rouschop, 2014). In 2015, gefitinib, one of the first-generation EGFR tyrosine kinase inhibitors (EGFR-TKIs), was approved by the United States Food and Drug Administration (USFDA) as a first-line treatment for metastatic NSCLC patients with activating EGFR mutations, resulting a longer progression-free survival (PFS) compared to standard cytotoxic chemotherapy (Gridelli et al., 2011; Douillard et al., 2014). Besides, previous studies also support that a considerable proportion of NSCLC patients harboring wild-type EGFR still achieve clinical benefit from gefitinib treatment (Zhou and Zhou, 2015; Shepherd, 2016).

Although gefitinib has a favorable clinical response, almost all patients will eventually develop acquired resistance after 10–14 months, which finally leads to treatment failure (Gandara et al., 2014). To date, many mechanisms of acquired resistance to gefitinib have been defined in around 60–70% of cases, which can be classified into three categories: secondary EGFR mutations, phenotypic transformation, and activation of alternative pathways (Morgillo et al., 2016). However, the mechanisms in about 30–40% of cases still remain unknown.

ATP-binding cassette (ABC) transporters are a family of membrane proteins that pump out of the cells a variety of endogenous and exogenous substrates in an ATP-dependent manner (Schinkel and Jonker, 2003). Nearly 40 years of research indicates that ABC-mediated multidrug efflux is one of the most important mechanisms of multidrug resistance (MDR), a major obstacle in the clinical treatment of various cancers. Due to the strong correlation between ABC transporters and MDR, a number of ABC inhibitors have been developed and tested in clinical trials. Unfortunately, the majority of trials did not confirm clinical benefit. There are multiple reasons for these negative results, but one of the main reason is the insufficient knowledge of the interactions between ABC transporters and chemotherapy drugs (Jaramillo et al., 2018; Mohammad et al., 2018; Robey et al., 2018). Owing to considerable overlap among the substrate profiles of the various ABC transporters, multiple transporters may be involved in the efflux of a specific chemotherapy agent. Therefore, it is critical that all known ABC transporters be studied within a single study, rather than focusing on individuals (Tamaki et al., 2011). In the case of gefitinib, only its interactions with ATP binding cassette transporter G2 (ABCG2), ATP binding cassette transporter B1 (ABCB1), and ATP binding cassette transporter C1 (ABCC1) have been examined previously. ABCG2 has been shown to be a high affinity gefitinib transporter, at least at submicromolar concentrations, and likely play an important role in acquired resistance to gefitinib (Leggas et al., 2006; Usuda et al., 2007; Azzariti et al., 2010; Chen et al., 2011; Hegedüs et al., 2012; Zhu et al., 2015). While ABCB1 and ABCC1 exhibit much lower affinities toward gefitinib (Ozvegy-Laczka et al., 2004; Beretta et al., 2017). However, no investigations into the interaction between other ABC transporters and gefitinib have been conducted so far.

In the present study, we mapped the expression of 48 human ABC transporters in the gefitinib-sensitive and -resistant NSCLC cell lines using RNA sequencing technology, and found that ABCC10 (ATP binding cassette subfamily C member 10), also

known as MDR protein 7 (MRP7), was significantly upregulated in cells with acquired resistance to gefitinib. Results from *in vitro* cell culture models and *in vivo* xenograft models showed that ABCC10 could actively pump gefitinib out of cells, and its overexpression led to a reduction in gefitinib sensitivity through decreasing the intracellular gefitinib accumulation.

ABCC10 is an important member of ABC transporter superfamily. Accumulating research has revealed that ABCC10 actively transports a broad range of cytotoxic chemotherapy agents, such as taxanes, vinca alkaloids, antifolates, cisplatin, daunorubicin, etoposide, irinotecan, epothilone B, as well as nucleoside analogs, leading to the occurrence of MDR (Wu et al., 2016; Dabrowska and Sirotak, 2017). Additionally, ABCC10 may interact with some EGFR-TKIs. A recent study has shown that lapatinib and erlotinib reverse ABCC10-mediated MDR through inhibition of the drug efflux function (Kuang et al., 2010). Here, our data suggest that ABCC10 has an important role in acquired resistance to gefitinib in NSCLC, which can serve as a novel predictive marker and a potential therapeutic target in gefitinib treatment.

MATERIALS AND METHODS

Cell Lines and Cultures

The EGFR-mutant PC9 (exon 19 deletion E746-A750) and EGFR wild-type H292 NSCLC cell lines, as well as Lewis lung carcinoma-porcine kidney epithelial cell line (LLC-PK1) were purchased from the Cellular Institute of Chinese Academy of Science. NSCLC cell lines were cultured with RPMI 1640 supplemented with 10% fetal bovine serum (FBS), and LLC-PK1 cells were maintained in complete Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% FBS. All the cell lines were cultured in a 5% CO₂ incubator at 37°C.

To establish acquired gefitinib-resistant cell lines PC9/GR and H292/GR, PC9 and H292 cells were continuously exposed to increasing dosages of gefitinib for ~12 months. Established resistant cell lines were maintained by culture in a medium containing 2 μmol/L gefitinib. To eliminate the effects of gefitinib, the resistant cells were cultured in a drug-free medium for at least 2 weeks before all experiments.

Establishment of Stable Cell Lines

The human *ABCC10* or *ABCG2* gene was inserted into the EcoRI and XbaI sites of pcDNA3.1(+) (Invitrogen, Carlsbad, CA) to make expression vectors, pcDNA3.1(+)/*ABCC10* or pcDNA3.1(+)/*ABCG2*.

To establish ABCC10-overexpressing NSCLC cells, gefitinib-sensitive PC9 and H292 cells were transfected with pcDNA3.1(+)/*ABCC10* or empty vector using Lipofectamine™ 2000 (Invitrogen, Carlsbad, CA, USA). To establish NSCLC cells with ABCC10 knockdown, *ABCC10* shRNA plasmid (shABCC10, Santa Cruz Biotechnology, sc-62641-SH) or control plasmid (shMock, Santa Cruz Biotechnology, sc-108060) was introduced into gefitinib-resistant NSCLC cells PC9/GR and H292/GR. Single colonies were identified in culture medium containing G418 (2 mg/mL) and subcultured for further analysis.

To establish the stably transfected LLC-PK1 cells expressing ABCC10 or ABCG2, pcDNA3.1(+)/ABCC10, or pcDNA3.1(+)/ABCG2 was transfected into LLC-PK1 cells, and stable transfected clones were selected as described above. Expression of ABCC10/ABCG2 was confirmed by quantitative real-time PCR and western blot analysis as described below.

Cell Viability Assay

Cell viability was measured using the CellTiter96 Aqueous One Solution Cell Proliferation Assay (MTS) (Promega, Madison, WI, United States). In brief, cells were plated in 96-well plates at the density of 2×10^4 cells per well. After 24 h incubation, cells were treated with various concentrations of gefitinib (0.1–10 $\mu\text{mol/L}$) for 72 h. Then, the 20 μL of MTS reagent was added to each well and the plates were incubated for an additional 2 h. The absorbance was read at 490 nm using a microplate reader (SynergyTMH4, BioTek, United States). Cell viability was calculated as a percentage relative to vehicle-treated control. The IC_{50} value was calculated based on the non-linear regression fit method by Graphpad Prism 4.0 software (San Diego, CA).

Cell Apoptosis Assay

For apoptosis assay by flow cytometry, cells were seeded in 6-well plates at a concentration of 2×10^5 cells per well, and treated with 1 $\mu\text{mol/L}$ gefitinib for 72 h. Cells were then digested with trypsin and washed with PBS three times, incubated with 5 μL of FITC-conjugated Annexin-V and 5 μL of propidium iodide (PI) (Thermo Fisher Scientific, MA, United States) for 15 min in a dark place at room temperature. The stained cells were detected using the BD Accuri C6 flow cytometer (BD Biosciences, CA, United States). At least 10,000 cells were analyzed for each group.

RNA Isolation and RNA Sequencing (RNA-Seq) Analysis

Total RNA was isolated from 1×10^7 cells using the mirVana™ miRNA ISOLATION Kit (Ambion, Austin, TX, United States) following the manufacturer's instruction. 1 μg of total RNA was used to prepare standard RNA-seq libraries (TruSeq Stranded Total RNA kit with Ribo-Zero Gold, Illumina). RNA integrity was validated for size using the Agilent 2100 Bioanalyzer (Agilent Technologies, CA, United States) and sequenced by a 2×125 bp paired-end sequencing module on an Illumina HiSeq 2500 (Oebiotech, Shanghai, China). The criteria for differential gene expression included a fold change ≥ 2 between compared groups and statistical significance at $P < 0.05$.

Reverse Transcription and Quantitative Real-Time PCR

Total RNA was isolated from the cells using TRIzol reagent (Invitrogen, Carlsbad, CA, United States), and the first strand cDNA was synthesized using the Revert Aid™ H Minus First Strand cDNA Synthesis Kit (TaKaRa Bio, Shiga, Japan) according to the manufacturer's instruction. Quantitative real-time PCR (qRT-PCR) was performed using SYBR Premix Ex Taq II (Takara Bio, Shiga, Japan) according to the manufacturer's instructions. The sequences of the ABCC10 primers were 5'-CGGGTTAAGCTTGTGACAGAGC-3' (forward) and 5'-AACACCTTGTTG

GCAGTGAGCT-3' (reverse). PCR programs were carried out as follows: 95°C for 30 s, followed by 40 cycles of 95°C for 5 sec, 60°C for 30 s. β -actin served as an internal control. Relative quantification of ABCC10 was analyzed using the $2^{-\Delta\Delta\text{Ct}}$ method as a ratio relative to the β -actin expression level in each sample (Livak and Schmittgen, 2001).

Protein Isolation and Western Blot Analysis

Crude membrane fraction from cells was isolated as described previously (Revalde et al., 2015). Total protein was extracted using RIPA buffer (Beyotime, Shanghai, China), with PMSF (Sigma, Missouri, United States). The Pierce BCA Protein Assay Kit (Thermo Fisher Scientific, Waltham, United States) was used to determine the protein concentration. The protein extracts were separated by 10% sodium dodecyl sulfate-polyacrylamide gel electrophoresis and transferred onto polyvinylidene difluoride membranes (Bio-Rad, Hercules, CA, United States). The membranes were incubated with anti-ABCC10, anti-ABCG2, anti- β -actin, and anti- Na^+/K^+ -ATPase primary antibodies (Abcam, Cambridge, United Kingdom) at 4°C overnight, probed with horseradish peroxidase-conjugated secondary antibodies (Abcam, Cambridge, United Kingdom), and signals were detected by ECL™ Prime (GE Healthcare, Buckinghamshire, United Kingdom) and a LAS-3000 imager (Fujifilm, Tokyo, Japan). β -actin and Na^+/K^+ -ATPase expression levels were used to normalize the total and membrane expression levels of ABCC10.

Measurement of Intracellular Gefitinib Accumulation Assay

Concentrations of gefitinib accumulated in cells were determined using a validated Liquid chromatography tandem mass spectrometry (LC-MS/MS) method. The cells were cultured in the 6-well plates at a density of 1×10^6 per well and were grown to 85% confluence. Then, the cells were treated with varying concentration of gefitinib with or without 2.5 $\mu\text{mol/L}$ cepharanthine at 37°C for 4 h, harvested and washed in cold PBS. Gefitinib was extracted from cells with 200 μL of a methanol/water mixture (50/50, v/v), cell extracts were centrifuged (4°C, 12,000 rpm/min, 10 min) and collected. Samples were prepared by adding 20 μL of internal standard solution (100 ng/mL, erlotinib) to 180 μL of the cell lysates. Cell proteins were quantified using the BCA Protein Assay kit (Thermo Scientific, Rockford, IL, United States). LC-MS/MS analysis was performed on an Agilent 1290 series liquid chromatography system (Agilent Technologies, Palo Alto, CA, United States) and an Agilent 6470 triple-quadrupole mass spectrometer (Agilent Technologies, Santa Clara, CA, United States). An Agilent ZORBAX Eclipse Plus C18 column (1.8 μm , 3.0 mm \times 50 mm) and a mobile phase [water (containing 0.1% formic acid) and methanol (30:70, v:v)] at a flow rate of 3 mL/min were applied. The ion transitions monitored were as follows: m/z 447.1 ($[\text{M}+\text{H}]^+$) to 128.4 ($[\text{M}+\text{H}]^+$) for gefitinib, and m/z 394.2 ($[\text{M}+\text{H}]^+$) to 336.1 ($[\text{M}+\text{H}]^+$) for erlotinib. The running time of each sample was 3 min. The lower limit of quantification for gefitinib was 1 ng/mL. The calibration curves were linear over the range 1–500 ng/mL.

with mean correlation coefficients of 0.9997. The intra- and inter-day coefficients of variation were <10%.

LLC-PK1 Monolayer Transport Assay

Polarized LLC-PK1 cells were used in transport assay. Wildtype LLC-PK1 (LLC-WT) cells, human *ABCC10* or *ABCG2* gene transfected LLC-PK1 (LLC-ABCC10 or LLC-ABCG2) cells were seeded on the permeable polycarbonate Transwell® cell culture inserts (24 mm diameter, 0.4 μm pore size; Costar, MA, United States) at a density of 2×10^6 per well for 72 h. Before the start of transport assay, cells were washed with PBS and preincubated with Opti-MEM (Invitrogen, Carlsbad, CA, United States) for 2 h, then the experiment was stated by replacing the medium on either the apical or the basal side of the cell layer with fresh DMEM containing 10% fetal calf serum and 10 nmol/L [³H]-estrone-3-sulfate, 100 nmol/L [³H]-paclitaxel, or 100 nmol/L [³H]-gefitinib with or without 2.5 μmol/L cepharanthine or 10 μmol/L Ko143. The cells were incubated at 37°C under 5% CO₂. After various time of incubation, 100 μL of medium was taken from each compartment, and the radioactivity in each aliquot was measured in a liquid scintillation counter (LS6500; Beckman Coulter, Inc., Fullerton, CA, United States). Immediately after each of the experiments, fluorescein isothiocyanate (FITC)-conjugated dextran (MW = 40 kDa) was used to examine the integrity of the cell monolayer. Leakage of dextran had to remain <1% of the total added radioactivity per hour. The apparent permeability (P_{app}) was calculated by the following equation

$$P_{app} = \frac{dQ/dt}{A \times C_0} \quad (1)$$

where Q is the amount of radioactivity transported across the monolayer, t is time, dQ/dt is the rate of transport, A is the effective surface area of the cell monolayer, and C_0 is the initial drug concentration. The efflux ratio (ER) was used as a measure of *ABCC10*/*ABCG2*-mediated efflux, and calculated according to Equation 2:

$$ER = \frac{P_{app} B \rightarrow A}{P_{app} A \rightarrow B} \quad (2)$$

where $P_{app} B \rightarrow A$ is the P_{app} value measured in the basal to apical direction, and $P_{app} A \rightarrow B$ is the P_{app} value measured in the apical to basal direction (Shaik et al., 2007).

NSCLC Xenograft Mice Models

The protocols of animal experiments were approved by the Animal Ethics and Experimental Committee of the Chongqing Medical University (Chongqing, China), and performed according to the National Institutes of Health Guide for the Care and Use of Laboratory Animals. Briefly, female Balb/c-nude mice (4–6 weeks, 16–20 g) were obtained from the Laboratory Animal Center of Chongqing Medical University (Chongqing, China), and randomized into four groups ($n = 6$). Mice subjected to subcutaneously injection with *ABCC10*-overexpressing PC9 cells (PC9-*ABCC10*), empty-vector transfected PC9 cells (PC9-EV), *ABCC10*-knockdown PC9/GR cells (PC9/GR-sh*ABCC10*), or

shMock-transfected PC9/GR cells (PC9/GR-shMock) (5×10^6 cells/mouse) in each right flank. When all tumors reached a mean volume of 50 mm³, the mice were treated with gefitinib (30 mg/kg/day) for 3 weeks by oral gavage. Tumor volume (TV) was calculated as formula: $TV \text{ (mm}^3\text{)} = (L \times W^2)/2$ (L , lone diameter; W , wide diameter). Body weights were recorded every 3 days. At the end of experiments, mice were sacrificed and the tumors were removed.

Immunohistochemical Staining

PC9 xenografts were collected, fixed in 4% paraformaldehyde, embedded in paraffin. Slides from each group were deparaffinized in xylene, and incubated with anti-Ki-67 antibodies (Abcam, Cambridge, United Kingdom). The primary antibody was detected with a biotinylated goat anti-rabbit IgG. Three slides per groups were read and scored for the number of Ki-67-positive cells using the Visiormorph Integrator image analysis system. The proliferating cells were estimated by the percentage of Ki-67 positive-stained cells in 10 randomly chosen high-powered fields for each section ($\times 400$).

Statistical Analysis

Statistical analysis was performed using the SPSS 20.0 software (IBM SPSS, Armonk, NY, United States). Heat map was performed by Clustering (version 3.17.1). All values were expressed as mean \pm SEM. One-way ANOVA and subsequent *post hoc* Tukey's test were performed to analyze the differences between sets of data. Values of $P < 0.05$ were considered statistically significant.

RESULTS

Gene Expression Profile of ABC Transporters in Gefitinib-Sensitive and -Resistant NSCLC Cell Lines

In order to explore a new mechanism of acquired resistance to gefitinib in NSCLC, the acquired gefitinib-resistant cell lines that were derived from the parental sensitive PC9 and H292 cells were established through continuous exposure of this drug, which were designated as PC9/GR and H292/GR. MTS proliferation assay was used to confirm the acquired resistance to gefitinib. The IC₅₀ values for gefitinib was 0.15 ± 0.03 μmol/L in PC9 cells, while PC9/GR cells showed about 32-fold resistance to gefitinib, with the IC₅₀ value of 4.65 ± 0.84 μmol/L. Similarly, the IC₅₀ was 1.01 ± 0.22 μmol/L in H292 cells, and the H292/GR showed about 11-fold higher resistance to gefitinib, with the IC₅₀ value of 10.90 ± 1.8 μmol/L (Figure 1).

The gene expression profile of 48 human ABC transporters in gefitinib-resistant PC9/GR and H292/GR cells were examined using RNA-seq and compared with that of the parental cell lines. The changes in transcription level of 48 genes encoding ABC transporters in the gefitinib-sensitive and -resistant NSCLC cell lines were shown in **Supplementary Tables 1, 2**. The reliability and the reproducibility between assays were assessed by repeating the experiments three times for each cell line ($n = 3$). The transcripts with a greater than 2-fold change in expression and an adjusted two-sided $P < 0.05$ were considered to have




FIGURE 1 | Cytotoxic effects of gefitinib in acquired gefitinib-resistant NSCLC cell lines and their parental cells. PC9, PC9/GR (A) and H292, H292/GR (B) cells were cultured in 96-well plates and exposed to the indicated concentrations of gefitinib for 72 h. The cell viability was analyzed using MTS assay as described in Materials and Methods. The number of viable cells is expressed as a percentage of the value for untreated cells. * $P < 0.05$, ** $P < 0.01$ compared to the parent-sensitive cell line.

significantly differential expression between two groups. **Figure 2** shows the data for one representative experiment. Compared to their parental cells, four genes encoding *ABCA1*, *ABCC10*, *ABCG2*, and *ABCE1* were significantly upregulated in PC9/GR cells, and five genes encoding *ABCC4*, *ABCC10*, *ABCD3*, *ABCG2*, and *ABCG1* were significantly upregulated in H292/GR cells. Therefore, the present results showed that except for *ABCG2*, a transporter that is known to be responsible for the acquired resistance to gefitinib in NSCLC (Leggas et al., 2006; Usuda et al., 2007; Azzariti et al., 2010; Chen et al., 2011; Hegedüs et al., 2012; Zhu et al., 2015), *ABCC10* was the only significant differential expressed transporter in both PC9/GR and H292/GR cells.

ABCC10 Is Overexpressed in Gefitinib-Resistant NSCLC Cell Lines

To verify the sequencing result, we quantitated the expression of *ABCC10* mRNA in gefitinib-sensitive and -resistant NSCLC cell lines using qRT-PCR. Our results showed that the expression patterns observed in all cell lines were consistent with the RNA-seq results. Compared to their parent-sensitive cell lines, *ABCC10* mRNA levels were increased about 10.9-fold in PC9/GR cells, and 8.3-fold in H292/GR cells (**Figure 3A**). Then, we examined the levels of ABCC10 protein in the lysates prepared from total and membrane proteins isolated from these cell lines. Increased total and plasma membrane ABCC10 levels were observed in cells with acquired resistance to gefitinib. Moreover, compared to the whole cell lysates, the upregulation of ABCC10 level was more obvious in the plasma membrane of two resistant cells (**Figure 3B**).

Influence of ABCC10 on Gefitinib Sensitivity in NSCLC Cells

To study the influence of ABCC10 on gefitinib sensitivity in NSCLC cells, we modulated the expression level of ABCC10 either by overexpression in gefitinib-sensitive NSCLC cells, or knockdown in gefitinib-resistant NSCLC cells (**Figure 4**), then observed the cytotoxic effect of gefitinib. Our results showed that compared with empty-vector-transfected cells, ABCC10 overexpression significantly increased the cell survival rate after



72 h of gefitinib exposure, the IC_{50} values were increased by 2.5-fold in PC9 cells, and 2.4-fold in H292 cells (**Figures 5A,B**). ABCC10 knockdown in gefitinib-resistant NSCLC cells caused about 38.5 and 34.1% reduction in IC_{50} values in PC9/GR and H292/GR cells, respectively (**Figures 5C,D**). In addition, after ABCC10 overexpression, gefitinib-induced apoptosis decreased from 27.7 to 15.3% in PC9 cells, and from 18.8 to 8.3% in H292 cells. Whereas ABCC10 knockdown led to increase rate of apoptosis from 6.6 to 10.4% in PC9/GR cells, and from 5.3 to 8.9% in H292/GR cells (**Figure 6**).

Influence of ABCC10 on Intracellular Concentration of Gefitinib in NSCLC Cells

The results above indicate that ABCC10 might play an important role in acquired resistance to gefitinib. Mechanistically, we detected the intracellular accumulation of gefitinib in NSCLC cells with different levels of ABCC10 expression. As shown in **Figure 7**, after ABCC10 overexpression, the intracellular gefitinib concentrations in gefitinib-sensitive PC9 and H292 cells were decreased by 25.3 and 23.7%, respectively. While after ABCC10 knockdown, the gefitinib-resistant cells showed higher intracellular concentration of gefitinib, 1.5-fold and 1.4-fold increases in PC9/GR and H292/GR cells, respectively. As expected, cepharranthine, an ABCC10 inhibitor (Zhou et al., 2009), could almost completely reverse the negative influence of ABCC10 on intracellular gefitinib accumulation (**Figure 7**).

ABCC10-Mediated Gefitinib Transport *in vitro*

As mentioned above, ABCC10 overexpression resulted in a decrease in the intracellular accumulation of gefitinib. Therefore, we evaluated whether gefitinib was a substrate of ABCC10 *in vitro*. As gefitinib is also a substrate of ABCG2, at least in the submicromolar concentration (Ozvegy-Laczka et al., 2004; Leggas et al., 2006; Azzariti et al., 2010; Hegedüs et al., 2012; Beretta et al., 2017), the ABCG2-mediated efflux of gefitinib was simultaneously observed in this study. Monolayers of wildtype LLC-PK1 (LLC-WT) cells, as well as its subclones transduced





with human *ABCC10* (LLC-ABCC10) or *ABCG2* (LLC-ABCG2) were used in this study (Figures 8A,B). The polarized LLC-ABCC10 and LLC-ABCG2 cells predominantly exported [³H]-paclitaxel and [³H]-estrone-3-sulfate, two typical substrates for ABCC10 and ABCG2 (Hopper-Borge et al., 2004; Nakayama et al., 2011), from the basal to apical side, which indicates that both ABCC10 and ABCG2 localize mainly to the apical membrane (Figure 8C). As for gefitinib, there was no significant difference in its permeability in either direction in LLC-WT cells. However, the basal-to-apical permeability of gefitinib in the LLC-ABCC10 and LLC-ABCG2 cells were significantly greater than the apical-to-basal permeability, yielding ER values of 7.8 and 10.3, respectively. The directional transport was abolished when the cells were treated with 2.5 $\mu\text{mol/L}$ cepharanthine (ABCC10 inhibitor) or 10 $\mu\text{mol/L}$ Ko143 (ABCG2 inhibitor), indicating that, in addition to ABCG2, gefitinib is a good substrate of human ABCC10 (Figure 8D).


We further observed the ABCC10 and ABCG2-mediated gefitinib efflux activity in the presence of various substrate concentration using LLC-WT, LLC-ABCC10, and LLC-ABCG2

cells. After incubation with varying concentrations of gefitinib for 4 h, the intracellular gefitinib accumulation was measured by LC-MS/MS assay. The results showed that LLC-ABCC10 and LLC-ABCG2 cells exhibited significantly lower intracellular accumulation of gefitinib at concentration of 1 and 10 $\mu\text{mol/L}$ than the LLC-WT cells. However, at the higher concentrations of 20 and 50 $\mu\text{mol/L}$, reduced cellular gefitinib accumulation was only observed in LLC-ABCC10 cells, not in LLC-ABCG2 cells, likely due to inhibition of ABCG2 activity at higher concentrations (Ozvegy-Laczka et al., 2004; Leggas et al., 2006; Figure 9).

Influence of ABCC10 on Gefitinib Sensitivity in NSCLC Xenograft Mice Models

To further determine whether ABCC10 could reduce the efficacy of gefitinib *in vivo*, PC9 xenograft models were established in female nude mice. Four cell lines, PC9-ABCC10, PC9-EV, PC9/GR-shABCC10, and PC9/GR-shMock were injected






subcutaneously into mice, and the mice began receiving gefitinib treatment when tumor volumes reached 50 mm³. After the 3-week treatment period, no significant alterations on average body weight were observed among groups (**Figure 10A**). Compared with PC9-EV group, the average TV and tumor weight showed 1.4-fold (231.4 \pm 94.5 mm³ vs. 168.3 \pm 77.7 mm³) and 1.3-fold (0.9 \pm 0.3g vs. 0.7 \pm 0.2g) increases in PC9-ABCC10 group. Similarly, compared with PC9/GR-shMock group, ABCC10 knockdown significantly decreased the average TV and tumor weight by 19% (365.8 \pm 96.5 mm³ vs. 452.1 \pm 86.3 mm³) and 12% (1.5 \pm 0.4g vs. 1.7 \pm 0.5g) in PC9/GR-shABCC10 group, respectively (**Figures 10B,C**). Additionally, we detected the expression of Ki-67, a well-known proliferation marker in NSCLC samples (Tabata et al., 2014). After ABCC10 overexpression, the percentage of Ki-67-positive cells was significantly increased from 21.1% in PC9-EV group to 30.8% in PC9-ABCC10 group. While

after ABCC10 knockdown, the percentage of Ki-67-positive cells was markedly decrease from 64.5% in PC9/GR-shMock group to 53.4% in PC9/GR-shABCC10 group (**Figure 10D**). These results suggested that ABCC10 could reduce the sensitivity of NSCLC cells to gefitinib *in vivo*, and inhibition of ABCC10 expression could partially restore the sensitivity to gefitinib.

DISCUSSION

ABC transporters play an important role in the absorption, distribution, and elimination of a wide variety of drugs in clinical use, including anticancer chemotherapeutic agents. Numerous studies has confirmed that ABC transporters play an essential role in the development of MDR to chemotherapy. These results lead to the development of three generations of ABC





inhibitors. However, despite a few early successes in preclinical studies, these inhibitors failed to improve the effectiveness of chemotherapy in clinical trials due to high toxicity and poor potency (Jaramillo et al., 2018; Mohammad et al., 2018; Robey et al., 2018). The toxicity of these inhibitors is mainly attributed to the inhibition of transporter expressed in normal tissues, and the cross reactivity with other ABC transporters or metabolism enzymes. For example, ABCB1 inhibitor valsopodar was found to increase anticancer drug exposure through cytochrome P450 3A4 (CYP3A4) inhibition, while elacrida and tariquidar were found to inhibit both ABCB1 and ABCG2 (de Bruin et al., 1999; Bates et al., 2001; Kannan et al., 2011). Recent developments in tumor-targeted drug delivery systems can be a promising approach to overcoming the side effects of these inhibitors (Binkhathlan and Lavasanifar, 2013; Callaghan et al., 2014). As for the insufficient potency of these inhibitors, one of the main causes may be the lack of full understanding of drug-transporter interactions in MDR. As we all know, one drug may be transported by multiple transporters. In MDR, more than one ABC transporter is likely to be involved in reducing drug accumulation, and the relative importance of these transporters is likely to vary among tumors (Tamaki et al., 2011). Since the expression of ABC transporters continue to be linked to poor outcome in clinic, more efforts should be devoted to investigate the functional aspects of ABC transporters in MDR. With these knowledge, even if the response to chemotherapy cannot be improved by ABC transporter inhibitor, we also can predict clinical response to certain drugs more accurately (Robey et al., 2018).

Recent research has suggested that some ABC transporters may alter the bioavailability of gefitinib at both the cellular and systemic levels, affecting the drug-target interaction and drug sensitivity (Beretta et al., 2017). But very little information is available till now. In the present study, we first established two NSCLC cell lines with acquired resistance to gefitinib, and aimed to identify more ABC transporters potentially involved in the mechanism of gefitinib resistance. In our


developed gefitinib-resistant cells, either *EGFR T790M* mutation or amplification of the *MET* proto-oncogene was observed (data not shown). To the best of our knowledge, this is the first work that shows the differential expression of 48 protein coding ABC transporters between gefitinib-sensitive and -resistant NSCLC cells. The RNA-Seq data analysis revealed that most of these transporters did not exhibit significant changes in their expression levels, only the expression levels of *ABCG2* and *ABCC10* transcripts were significantly changed in both *EGFR* mutant (PC9) and wild-type (H292) NSCLC cell lines simultaneously. The significantly elevated *ABCG2* expression in acquired gefitinib-resistant NSCLC cells has been shown previously both *in vitro* and *in vivo* (Usuda et al., 2007; Zhu et al., 2015), but the involvement of *ABCC10* in the acquired resistance to *EGFR*-TKIs has not been reported so far. In this study, we found that both total and cellular membrane *ABCC10* protein levels were significantly increased in acquired gefitinib-resistant NSCLC cells, and the increase of membrane *ABCC10* level was more obvious than that of the total *ABCC10* level. These results imply that some factors may influence the processes of biogenesis and traffic of *ABCC10* in NSCLC cells with acquired resistance to gefitinib. To date, mechanisms that regulate *ABCC10* expression are largely unknown. Two transcription factors, specificity protein 1 (Sp1) and E2 factor (E2F), as well as NIMA-related expressed kinase 2 (NEK2) have been shown to be involved in the *ABCC10* expression regulation (Dabrowska and Sirotnak, 2004; Wu et al., 2017). In addition, some microRNAs, such as several members of let-7 family are referred to downregulate the *ABCC10* level (Borel et al., 2012; Wu et al., 2016). Interestingly, previous studies have suggested that many microRNAs play important role in gefitinib resistance, and may also take part in the process of protein membrane trafficking (Sun et al., 2015; Zang et al., 2017). Therefore, regulatory factors, especially microRNAs, that are likely to influence the biogenesis and traffic of *ABCC10* in NSCLC cells with acquired resistance to gefitinib warrant further investigation.

Next, we aimed to explore the role of *ABCC10* in acquired resistance to gefitinib in NSCLC. We found that *ABCC10* decreased the intracellular gefitinib concentration, prevented NSCLC cells from gefitinib-induced growth inhibition and apoptosis *in vitro*. And as expected, *ABCC10* also enhanced tumor growth in gefitinib-treated NSCLC xenograft models. Therefore, we hypothesized that *ABCC10* might decrease gefitinib sensitivity through pumping out gefitinib from NSCLC cells. To further address this issue, we performed *in vitro* transport study of gefitinib at submicromolar concentration in *ABCC10*-overexpressing LLC-PK1 cell monolayers. We found that *ABCC10* could actively pump gefitinib out of cells, with an ER value of 7.8. According to a white paper published by International Transporter Consortium (ITC), a compound is considered a potential substrate of apically localized transporters if its transport ratio is ≥ 2 (International Transporter Consortium et al., 2010). Moreover, cepharanthine, an *ABCC10* inhibitor, almost completely inhibited gefitinib efflux from LLC-*ABCC10* cells. Based on these results, we conclude that, for



the first time, ABCC10 actively mediates the transport of gefitinib, and is involved in acquired resistance to gefitinib in NSCLC cells.

To our knowledge only three members of ABC transporter subfamily (i.e., ABCG2, ABCB1, and ABCC1) have been examined with respect to their gefitinib efflux activities so far.



Unfortunately, previous study has shown that gefitinib exhibits little or no affinity for ABCB1 and ABCC1 (Ozvegy-Laczka et al., 2004). Considering no changes in the levels of these two transporters were observed in our gefitinib-resistant NSCLC cells, we come to a conclusion that ABCB1 and ABCC1 are unlikely to play a role in the development of acquired resistance to gefitinib in NSCLC. Although it is well established that gefitinib is able to interact with ABCG2, there is, however, controversy over whether gefitinib is a substrate or inhibitor of ABCG2. Some studies have shown that gefitinib is actively extruded by ABCG2, while others indicate that gefitinib is an inhibitor but not a substrate of ABCG2. It is now generally believed that gefitinib can be efflux by ABCG2 at submicromolar concentrations, whereas at higher concentrations it is likely to act as an inhibitor (Ozvegy-Laczka et al., 2004; Leggas et al., 2006; Azzariti et al., 2010; Hegedüs et al., 2012; Beretta et al., 2017). In the present study, we also observed the ABCG2-mediated transport of gefitinib at submicromolar concentration, the unbound plasma level of gefitinib. We found an active efflux of gefitinib by ABCG2, with an ER value of 10.3. This indicates that at submicromolar concentration, the ABCG2-mediated gefitinib transport activity is higher than that of ABCC10. Consistently, we found a lower intracellular gefitinib accumulation in the LLC-ABCG2 cells than in the LLC-ABCC10 cells after 1 $\mu\text{mol/L}$ gefitinib incubation. However, the intracellular gefitinib accumulation in the LLC-ABCG2 cells tend to be higher than in the LLC-ABCC10 cells after 10 $\mu\text{mol/L}$ gefitinib incubation. And at more higher gefitinib concentrations, no significant decrease in intracellular gefitinib concentration could be observed in the LLC-ABCG2 cells compared with LLC-WT cells, but still could

be detected in the LLC-ABCC10 cells. These results indicate that ABCG2-mediated gefitinib efflux activity will be decreased with the increase of gefitinib concentration, but ABCC10 can activity extrude gefitinib even at concentration as high as 50 $\mu\text{mol/L}$. Considering the gefitinib concentration in NSCLC tumor tissues is more than 40-fold higher than plasma levels, we speculate that ABCC10 may play a more important role than ABCG2 in acquired resistance to gefitinib *in vivo* (McKillop et al., 2005; Haura et al., 2010).

In summary, our results show that ABCC10 is overexpressed in NSCLC cells with acquired resistance to gefitinib, independent of EGFR mutation status. As a substrate, gefitinib can be actively transported by ABCC10, even at concentration as high as 50 $\mu\text{mol/L}$. ABCC10-mediated gefitinib efflux leads to a decrease in the intracellular accumulation, as well as antitumor efficacy of gefitinib in NSCLC *in vitro* and *in vivo*. This study shed more light on the factors that influence acquired resistance to gefitinib, and proposes that ABCC10 can be as a novel predictive marker, as well as a potential therapeutic target for gefitinib acquired resistance in NSCLC.

AUTHOR CONTRIBUTIONS

HZha, YH, and JS performed the experiments and analyzed the data. HZha and YD interpreted the data and drafted the manuscript. LW and HZho designed the study, supervised the work and wrote the final version of the manuscript. All authors agree to be accountable for the content of the work.

FUNDING

This work was supported by the National Scientific Foundation of China (No. 81473284, 81571457).

REFERENCES

- Azzariti, A., Porcelli, L., Simone, G. M., Quatrala, A. E., Colabufo, N. A., Berardi, F., et al. (2010). Tyrosine kinase inhibitors and multidrug resistance proteins: interactions and biological consequences. *Cancer Chemother. Pharmacol.* 65, 335–346. doi: 10.1007/s00280-009-1039-0
- Bates, S., Kang, M., Meadows, B., Bakke, S., Choyke, P., Merino, M., et al. (2001). A phase I study of infusional vinblastine in combination with the P-glycoprotein antagonist PSC 833 (valsopodar). *Cancer* 92, 1577–1590. doi: 10.1002/1097-0142(20010915)92:6<1577::AID-CNCR1484>3.0.CO;2-H
- Beretta, G. L., Cassinelli, G., Pennati, M., Zuco, V., and Gatti, L. (2017). Overcoming ABC transporter-mediated multidrug resistance: the dual role of tyrosine kinase inhibitors as multitargeting agents. *Eur. J. Med. Chem.* 142, 271–289. doi: 10.1016/j.ejmech.2017.07.062
- Binkhathlan, Z., and Lavasanifar, A. (2013). P-glycoprotein inhibition as a therapeutic approach for overcoming multidrug resistance in cancer: current status and future perspectives. *Curr. Cancer Drug Targets.* 13, 326–346. doi: 10.2174/15680096113139990076
- Borel, F., Han, R., Visser, A., Petry, H., van Deventer, S. J., Jansen, P. L., et al. (2012). Adenosine triphosphate-binding cassette transporter genes up-regulation in untreated hepatocellular carcinoma is mediated by cellular microRNAs. *Hepatology* 55, 821–832. doi: 10.1002/hep.24682
- Callaghan, R., Luk, F., and Bebaawy, M. (2014). Inhibition of the multidrug resistance P-glycoprotein: time for a change of strategy? *Drug Metab. Dispos.* 42, 623–631. doi: 10.1124/dmd.113.056176
- Chen, Y. J., Huang, W. C., Wei, Y. L., Hsu, S. C., Yuan, P., Lin, H. Y., et al. (2011). Elevated BCRP/ABCG2 expression confers acquired resistance to gefitinib in wild-type EGFR-expressing cells. *PLoS ONE* 6:e21428. doi: 10.1371/journal.pone.0021428
- Dabrowska, M., and Sirotnak, F. M. (2004). Regulation of transcription of the human MRP7 gene. Characteristics of the basal promoter and identification of tumor-derived transcripts encoding additional 5' end heterogeneity. *Gene* 341, 129–139. doi: 10.1016/j.gene.2004.06.022
- Dabrowska, M., and Sirotnak, F. M. (2017). E2F site in the essential promoter region does not confer S phase-specific transcription of the ABCC10 gene in human prostate cancer cells. *Acta Biochim. Pol.* 64, 371–374. doi: 10.18388/abp.2017_1521
- de Bruin, M., Miyake, K., Litman, T., Robey, R., and Bates, S. E. (1999). Reversal of resistance by GF120918 in cell lines expressing the ABC half-transporter, MXR. *Cancer Lett.* 146, 117–126. doi: 10.1016/S0304-3835(99)00182-2
- Douillard, J. Y., Ostoros, G., Cobo, M., Ciuleanu, T., McCormack, R., Webster, A., et al. (2014). First-line gefitinib in Caucasian EGFR mutation-positive NSCLC patients: a phase-IV, open-label, single-arm study. *Br. J. Cancer* 110, 55–62. doi: 10.1038/bjc.2013.721
- Ennis, B. W., Lippman, M. E., and Dickson, R. B. (1991). The EGF receptor system as a target for antitumor therapy. *Cancer Invest.* 9, 553–562. doi: 10.3109/07357909109018953
- Gandara, D. R., Li, T., Lara, P. N., Kelly, K., Riess, J. W., Redman, M. W., et al. (2014). Acquired resistance to targeted therapies against oncogene-driven non-small-cell lung cancer: approach to subtyping progressive disease and clinical implications. *Clin. Lung Cancer* 15, 1–6. doi: 10.1016/j.clc.2013.10.001
- Gridelli, C., De Marinis, F., Di Maio, M., Cortinovis, D., Cappuzzo, F., and Mok, T. (2011). Gefitinib as first-line treatment for patients with advanced non-small-cell lung cancer with activating epidermal growth factor receptor mutation: implications for clinical practice and open issues. *Lung Cancer* 72, 3–8. doi: 10.1016/j.lungcan
- Haura, E. B., Sommers, E., Song, L., Chiappori, A., and Becker, A. (2010). A pilot study of preoperative gefitinib for early-stage lung cancer to assess intratumor drug concentration and pathways mediating primary resistance. *J. Thorac. Oncol.* 5, 1806–1814. doi: 10.1097/JTO.0b013e3181f38f70
- Hegedüs, C., Truta-Feles, K., Antalffy, G., Várady, G., Németh, K., Ozvegy-Laczka, C., et al. (2012). Interaction of the EGFR inhibitors gefitinib, vandetanib, pelitinib and neratinib with the ABCG2 multidrug transporter: implications for the emergence and reversal of cancer drug resistance. *Biochem. Pharmacol.* 84, 260–267. doi: 10.1016/j.bcp.2012.04.010
- Hopper-Borge, E., Chen, Z. S., Shchavezleva, I., Belinsky, M. G., and Kruh, G. D. (2004). Analysis of the drug resistance profile of multidrug resistance protein 7 (ABCC10): resistance to docetaxel. *Cancer Res.* 64, 4927–4930. doi: 10.1158/0008-5472.CAN-03-3111
- International Transporter Consortium, Giacomini, K. M., Huang, S. M., Tweedie, D. J., Benet, L. Z., Brouwer, K. L., et al. (2010). Membrane transporters in drug development. *Nat. Rev. Drug Discov.* 9, 215–236. doi: 10.1038/nrd3028
- Jaramillo, A. C., Saig, F. A., Cloos, J., Jansen, G., and Peters, G. J. (2018). How to overcome ATP-binding cassette drug efflux transporter-mediated drug resistance? *Cancer Drug Resist.* 1, 6–29. doi: 10.20517/cdr.2018.02
- Jutten, B., and Rouschop, K. M. (2014). EGFR signaling and autophagy dependence for growth, survival, and therapy resistance. *Cell Cycle* 13, 42–51. doi: 10.4161/cc.27518
- Kannan, P., Telu, S., Shukla, S., Ambudkar, S. V., Pike, V. W., Halldin, C., et al. (2011). The “specific” P-glycoprotein inhibitor Tariquidar is also a substrate and an inhibitor for breast cancer resistance protein (BCRP/ABCG2). *ACS Chem. Neurosci.* 2, 82–89. doi: 10.1021/cn100078a
- Kuang, Y. H., Shen, T., Chen, X., Sodani, K., Hopper-Borge, E., Tiwari, A. K., et al. (2010). Lapatinib and erlotinib are potent reversal agents for MRP7 (ABCC10)-mediated multidrug resistance. *Biochem. Pharmacol.* 79, 154–161. doi: 10.1016/j.bcp.2009.08.021
- Leggas, M., Panetta, J. C., Zhuang, Y., Schuetz, J. D., Johnston, B., Bai, F., et al. (2006). Gefitinib modulates the function of multiple ATP-binding cassette transporters *in vivo*. *Cancer Res.* 66, 4802–4807. doi: 10.1158/0008-5472.CAN-05-2915
- Livak, K. J., and Schmittgen, T. D. (2001). Analysis of relative gene expression data using real-time quantitative PCR and the $2^{-\Delta\Delta C_T}$ Method. *Methods* 25, 402–408. doi: 10.1006/meth.2001.1262
- McKillop, D., Partridge, E. A., Kemp, J. V., Spence, M. P., Kendrew, J., Barnett, S., et al. (2005). Tumor penetration of gefitinib (Iressa), an epidermal growth factor receptor tyrosine kinase inhibitor. *Mol. Cancer Ther.* 4, 641–649. doi: 10.1158/1535-7163.MCT-04-0329
- Mohammad, I. S., He, W., and Yin, L. (2018). Understanding of human ATP binding cassette superfamily and novel multidrug resistance modulators to overcome MDR. *Biomed. Pharmacother.* 100, 335–348. doi: 10.1016/j.biopha.2018.02.038
- Morgillo, F., Della Corte, C. M., Fasano, M., and Ciardiello, F. (2016). Mechanisms of resistance to EGFR-targeted drugs: lung cancer. *ESMO Open* 1:e000060. doi: 10.1136/esmoopen-2016-000060
- Nakayama, A., Matsuo, H., Takada, T., Ichida, K., Nakamura, T., Ikebuchi, Y., et al. (2011). ABCG2 is a high-capacity urate transporter and its genetic impairment increases serum uric acid levels in humans. *Nucleosides Nucleotides Nucleic Acids.* 30, 1091–1097. doi: 10.1080/15257770.2011.633953
- Ozvegy-Laczka, C., Hegedus, T., Várady, G., Ujhelly, O., Schuetz, J. D., Váradi, A., et al. (2004). High-affinity interaction of tyrosine kinase inhibitors with the ABCG2 multidrug transporter. *Mol. Pharmacol.* 65, 1485–1495. doi: 10.1124/mol.65.6.1485
- Revalde, J. L., Li, Y., Hawkins, B. C., Rosengren, R. J., and Paxton, J. W. (2015). Heterocyclic cyclohexanone monocarbonyl analogs of curcumin can inhibit the

SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: <https://www.frontiersin.org/articles/10.3389/fphar.2018.01312/full#supplementary-material>

- activity of ATP-binding cassette transporters in cancer multidrug resistance. *Biochem. Pharmacol.* 93, 305–317. doi: 10.1016/j.bcp.2014.12.012
- Ridge, C. A., McErlean, A. M., and Ginsberg, M. S. (2013). Epidemiology of lung cancer. *Semin. Intervent. Radiol.* 30, 93–98. doi: 10.1055/s-0033-1342949
- Robey, R. W., Pluchino, K. M., Hall, M. D., Fojo, A. T., Bates, S. E., and Gottesman, M. M. (2018). Revisiting the role of ABC transporters in multidrug-resistant cancer. *Nat. Rev. Cancer* 18, 452–464. doi: 10.1038/s41568-018-0005-8
- Salomon, D. S., Brandt, R., Ciardiello, F., and Normanno, N. (1995). Epidermal growth factor-related peptides and their receptors in human malignancies. *Crit. Rev. Oncol. Hematol.* 19, 183–232. doi: 10.1016/1040-8428(94)00144-1
- Schinkel, A. H., and Jonker, J. W. (2003). Mammalian drug efflux transporters of the ATP binding cassette (ABC) family: an overview. *Adv. Drug. Deliv. Rev.* 55, 3–29. doi: 10.1016/S0169-409X(02)00169-2
- Shaik, N., Giri, N., Pan, G., and Elmquist, W. F. (2007). P-glycoprotein-mediated active efflux of the anti-HIV1 nucleoside abacavir limits cellular accumulation and brain distribution. *Drug Metab. Dispos.* 35, 2076–2085. doi: 10.1124/dmd.107.017723
- Shepherd, F. A. (2016). Should EGFR tyrosine kinase inhibitors be used in non-small cell lung cancer in the absence of EGFR mutations? Yes, there is a role for EGFR TKIs in these patients. *Clin. Adv. Hematol. Oncol.* 14, 41–43.
- Sun, L. H., Yan, M. L., Hu, X. L., Peng, L. W., Che, H., Bao, Y. N., et al. (2015). MicroRNA-9 induces defective trafficking of Nav1.1 and Nav1.2 by targeting Navβ2 protein coding region in rat with chronic brain hypoperfusion. *Mol. Neurodegener.* 10:36. doi: 10.1186/s13024-015-0032-9
- Tabata, K., Tanaka, T., Hayashi, T., Hori, T., Nunomura, S., Yonezawa, S., et al. (2014). Ki-67 is a strong prognostic marker of non-small cell lung cancer when tissue heterogeneity is considered. *BMC Clin. Pathol.* 14:23. doi: 10.1186/1472-6890-14-23
- Tamaki, A., Ierano, C., Szakacs, G., Robey, R. W., and Bates, S. E. (2011). The controversial role of ABC transporters in clinical oncology. *Essays Biochem.* 50, 209–232. doi: 10.1042/bse0500209
- Tas, F., Ciftci, R., Kilic, L., and Karabulut, S. (2013). Age is a prognostic factor affecting survival in lung cancer patients. *Oncol. Lett.* 6, 1507–1513. doi: 10.3892/ol.2013.1566
- Usuda, J., Ohira, T., Suga, Y., Oikawa, T., Ichinose, S., Inoue, T., et al. (2007). Breast cancer resistance protein (BCRP) affected acquired resistance to gefitinib in a “never-smoked” female patient with advanced non-small cell lung cancer. *Lung Cancer* 58, 296–299. doi: 10.1016/j.lungcan.2007.05.019
- Wu, K., Yang, Y., Zhao, J., and Zhao, S. (2016). BAG3-mediated miRNA let-7g and let-7i inhibit proliferation and enhance apoptosis of human esophageal carcinoma cells by targeting the drug transporter ABCC10. *Cancer Lett.* 371, 125–133. doi: 10.1016/j.canlet.2015.11.031
- Wu, S. M., Lin, S. L., Lee, K. Y., Chuang, H. C., Feng, P. H., Cheng, W. L., et al. (2017). Hepatoma cell functions modulated by NEK2 are associated with liver cancer progression. *Int. J. Cancer* 140, 1581–1596. doi: 10.1002/ijc.30559
- Zang, H., Wang, W., and Fan, S. (2017). The role of microRNAs in resistance to targeted treatments of non-small cell lung cancer. *Cancer Chemother. Pharmacol.* 79, 227–231. doi: 10.1007/s00280-016-3130-7
- Zhou, F., and Zhou, C. C. (2015). Targeted therapies for patients with advanced NSCLC harboring wild-type EGFR: what's new and what's enough. *Chin. J. Cancer* 34, 310–319. doi: 10.1186/s40880-015-0036-4
- Zhou, Y., Hopper-Borge, E., Shen, T., Huang, X. C., Shi, Z., Kuang, Y. H., et al. (2009). Cepharanthine is a potent reversal agent for MRP7(ABCC10)-mediated multidrug resistance. *Biochem. Pharmacol.* 77, 993–1001. doi: 10.1016/j.bcp.2008.12.005
- Zhu, Y., He, W., Gao, X., Li, B., Mei, C., Xu, R., et al. (2015). Resveratrol overcomes gefitinib resistance by increasing the intracellular gefitinib concentration and triggering apoptosis, autophagy and senescence in PC9/G NSCLC cells. *Sci. Rep.* 5:17730. doi: 10.1038/srep17730

Conflict of Interest Statement: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2018 Zhao, Huang, Shi, Dai, Wu and Zhou. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.